申请人:Shenzhen Salubris Pharmaceuticals Co., Ltd.
公开号:EP2592083A1
公开(公告)日:2013-05-15
Fused quinazoline derivatives and uses thereof as protein tyrosine kinase inhibitors and aurora kinase inhibitors are disclosed. Said protein tyrosine kinase inhibitors and aurora kinase inhibitors can be used in treating cancers, leukaemia and the diseases relevant to differentiation and proliferation. Said protein tyrosine kinase and aurora kinase dual inhibitors are the compounds represented by the following general formula or salts thereof.
本研究公开了融合喹唑啉衍生物及其作为蛋白酪氨酸激酶抑制剂和极光激酶抑制剂的用途。所述蛋白酪氨酸激酶抑制剂和极光激酶抑制剂可用于治疗癌症、白血病以及与分化和增殖有关的疾病。所述蛋白酪氨酸激酶和极光激酶双重抑制剂为下通式所代表的化合物或其盐类。